Sp1046

AGA GUIDELINE: BIOMARKERS FOR MONITORING INFLAMMATION IN IBD

Date
May 9, 2023
Explore related products in the following collection:

Society: AGA

AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology. This session will give DDW attendees the rare opportunity to hear about newly published and upcoming AGA guidelines from the authors of the guideline themselves, including a Question and Answer portion. It also provides an additional public forum to have the guidelines heard and discussed, in addition to our 30-day public comment period, contributing to an open and transparent process of guideline development.

Presenters

Speaker Image for Siddharth Singh
University of California San Diego

Tracks

Related Products

Thumbnail for PLACEHOLDER
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
Thumbnail for AGA Guidelines Highlights 2023
AGA Guidelines Highlights 2023
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for INTRODUCTION
INTRODUCTION
AGA guidelines are among the most rigorously evidence-based and trusted guidelines in the field of GI and hepatology…